法国 2024 年出现了 ，包括一个耐大环内酯的分离株。
Resurgence of , including one macrolide-resistant isolate, France, 2024.
机构信息
These authors contributed equally to this work and share first authorship.
National Reference Center for Whooping Cough and other Bordetella infections, Institut Pasteur, Paris, France.
出版信息
Euro Surveill. 2024 Aug;29(31). doi: 10.2807/1560-7917.ES.2024.29.31.2400459.
As other European countries, France is experiencing a resurgence of pertussis in 2024. Between 1 January and 31 May 2024, 5,616 (24.9%) positive qPCR tests were identified, following a 3-year period of almost null incidence. Of 67 cultured and whole genome sequenced isolates, 66 produced pertactin and 56 produced FIM2, in contrast to pre-COVID-19 years. One isolate of genotype Bp-AgST4 was resistant to macrolides. Pertussis resurgence may favour isolates that produce FIM2 and pertactin.
与其他欧洲国家一样，法国在 2024 年也经历了百日咳的死灰复燃。在 2024 年 1 月 1 日至 5 月 31 日期间，在经历了近 3 年几乎零发病率后，有 5616 例（24.9%）经 qPCR 检测呈阳性。在 67 株培养和全基因组测序的分离株中，66 株产生 pertactin，56 株产生 FIM2，与 COVID-19 之前的年份形成对比。一株 Bp-AgST4 基因型的分离株对大环内酯类药物具有耐药性。百日咳的死灰复燃可能有利于产生 FIM2 和 pertactin 的分离株。
Zotero 插件